- As China Slows Down, the Philippines Moves to Grab Foreign Investment
- Why Obamacare Subsidies Should Be Struck Down by the Supreme Court
- MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
- Shale Oil Bust Enters Phase Two, Led by Hercules and SandRidge
- Comcast Wants Congress to Gut the New Net Neutrality Rules
Alexza expects US and European regulators to announce approval decisions in December.
Traders are already bidding up shares of Celsion in anticipation of pivotal trial results.
Supernus share should fall now that 10 million shares under lock-up can now be sold.
Traders need to be less cocky and more prepared for when stocks fall.
The biotech bull market has created a new category of swing trade catalysts.
Biotech swing trader Mark Messier warns to look at Hemispherx as a short-term trade, not an investment.
Get in Zogenix early before other traders start speculating over its chronic pain drug Zohydro.
Biotech trader Mark Messier explains how to position trades ahead of two important biotech clinical trials.
Biotech trader Mark Messier explains how to swing trade Dynavax into a Nov. 14 FDA advisory panel.